Loading institutional data...
Loading institutional data...
Insufficient data to determine institutional momentum.
Data as of Q3 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading analysis...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading insider activity...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Top 11 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned on $201.7M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Operating income fell despite reinvestment — a warning on capital productivity. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Interest is easily covered by operating profit.
Cash vs short-term debt unavailable.
Short-term / long-term split not separately reported.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Educational — not a recommendation.
Solve the discounted cash flow backwards, then stress-test the assumptions.
Average free cash flow across the last 3 positive fiscal years (FY2023, FY2024, FY2025). Smooths the cycle. Stock compensation is NOT charged — it is added back inside operating cash flow.
To be worth $21.26 today, the market must believe free cash flow compounds -30.3%/yr for a decade (off $347.6M on the 3-yr avg basis).
The market's -30.3% is more conservative than its 8-yr track record.
Default is 8.0% — this company's computed cost of capital (computed WACC), the same rate the Analysis tab discounts at.
2-stage DCF · 0.04B shares (market data) · net debt -$44.3M
Today's price is outside this grid at every discount rate shown — the assumptions it requires lie beyond the plotted range, which is itself the finding.
mean -6.9% · volatility σ 23% · implied rate exceeded in 7/8 yrs
Central path = implied -30.3%/yr growth; shaded band = ±1σ (23%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
EOD close · as of 2026-10-30
How a revenue dollar becomes profit — FY2025
Dividends and buybacks are cash paid out, shown here against the same year's profit for scale — not funded from it.
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.17B 100.0% | $1.14B 100.0% | $1.19B 100.0% | $1.59B 100.0% | $1.21B 100.0% | $966.7M 100.0% | $1.09B 100.0% | $1.29B 100.0% | $1.17B 100.0% | $986.7M 100.0% |
| Cost of Revenue | $818.8M 70.2% | $717.0M 63.1% | $803.3M 67.5% | $1.22B 76.3% | $773.2M 63.6% | $587.8M 60.8% | $712.4M 65.2% | $908.5M 70.7% | $769.3M 65.6% | $595.4M 60.3% |
| Cost of Products | — | — | — | — | — | — | — | — | $769.3M 65.6% | $595.4M 60.3% |
| Gross Profit | $347.8M 29.8% | $418.9M 36.9% | $387.5M 32.5% | $377.4M 23.7% | $441.7M 36.4% | $378.9M 39.2% | $379.4M 34.8% | $377.2M 29.3% | $403.7M 34.4% | $391.3M 39.7% |
| Selling, General & Admin | $28.3M 2.4% | $28.5M 2.5% | $29.8M 2.5% | $29.7M 1.9% | $31.0M 2.6% | $25.9M 2.7% | $29.3M 2.7% | $27.6M 2.1% | $29.3M 2.5% | $24.9M 2.5% |
| Operating Income | $319.6M 27.4% | $390.4M 34.4% | $357.7M 30.0% | $347.7M 21.8% | $410.7M 33.8% | $353.0M 36.5% | $350.1M 32.1% | $349.6M 27.2% | $374.4M 31.9% | $366.4M 37.1% |
| Interest Expense | $22.9M 2.0% | $25.7M 2.3% | $26.5M 2.2% | $13.4M 0.8% | — | — | — | — | — | — |
| Other Income (Expense), net | $2.4M 0.2% | $5.3M 0.5% | $4.2M 0.4% | $1.6M 0.1% | $62K 0.0% | $733K 0.1% | $3.1M 0.3% | $2.5M 0.2% | $1.8M 0.2% | $601K 0.1% |
| Pretax Income | $299.1M 25.6% | $370.0M 32.6% | $335.4M 28.2% | $335.8M 21.1% | $401.9M 33.1% | $341.7M 35.3% | $333.6M 30.6% | $330.6M 25.7% | $354.3M 30.2% | $354.4M 35.9% |
| Income Tax Expense | $547K 0.0% | $835K 0.1% | $813K 0.1% | $1.0M 0.1% | $549K 0.0% | $564K 0.1% | $728K 0.1% | $22K 0.0% | $1.3M 0.1% | $1.0M 0.1% |
| Net Income | $48.7M 4.2% | $62.4M 5.5% | $54.3M 4.6% | $64.2M 4.0% | $82.5M 6.8% | $66.2M 6.8% | $61.0M 5.6% | $49.3M 3.8% | $48.7M 4.1% | $40.9M 4.1% |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Ranked against 39 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-09-30.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AMPH | $1.2B | 13.7× | 9.5× | 1.6× | -1.7% | 49.5% | 13.6% | 12.4% | 7.0% | 2.6× | 44 |
| MRVI | $1.2B | — | — | 6.3× | -28.3% | 18.3% | -70.4% | -61.6% | -25.9% | — | 20 |
| MNKD | $1.1B | 175.0× | 30.0× | 3.2× | 22.2% | 92.3% | 1.7% | -11.5% | 1.9% | 6.0× | 48 |
| ECVT | $1.1B | — | 9.8× | 1.5× | 20.9% | 21.8% | -9.8% | -11.8% | -7.1% | 1.5× | 28 |
| HROW | $1.1B | — | — | 3.9× | 36.4% | 75.1% | -1.9% | -9.8% | -1.7% | — | 36 |
| ODD | $1000M | 12.0× | 4.6× | 1.2× | 25.2% | 72.7% | 13.7% | 27.9% | 27.9% | -3.1× | 25 |
| GPRE | $988M | — | 38.5× | 0.5× | -14.9% | 6.5% | -5.8% | -15.8% | -10.4% | 6.8× | 31 |
| FMC | $964M | — | — | 0.3× | -18.3% | 37.0% | -64.6% | -108% | -40.3% | — | 80 |
| RIGL | $958M | 2.6× | 7.6× | 3.3× | 64.1% | 93.3% | — | 93.8% | 82.7% | 0.1× | 29 |
| FTK | $918M | 30.2× | 38.0× | 3.9× | 26.9% | 25.2% | 12.9% | 27.0% | 19.9% | 1.4× | 18 |
| TBPH | $884M | 8.3× | — | 8.2× | 66.9% | — | 98.5% | 35.7% | 35.7% | — | 1 |
| CYRX | $876M | 12.3× | — | 5.0× | 12.4% | 47.1% | 44.4% | 15.6% | 15.6% | — | 26 |
| KRO | $863M | — | 57.8× | 0.5× | -1.5% | 11.5% | -6.0% | -14.8% | -8.5% | — | 21 |
| LXU | $829M | 33.9× | 9.1× | 1.4× | 17.8% | 17.0% | 4.0% | 4.7% | 2.5% | 3.1× | 26 |
| ARDX | $782M | — | — | 1.9× | 22.1% | 90.3% | -15.1% | -36.9% | -16.7% | — | 30 |
| COLL | $775M | 13.8× | 3.0× | 1.0× | 23.6% | 59.3% | 8.1% | 20.8% | 20.8% | -1.3× | 40 |
| WLKP | $749M | — | 1.6× | 0.6× | 2.7% | 29.8% | 4.2% | — | — | -0.1× | 9 |
| LXRX | $632M | — | — | 12.7× | 60.2% | 99.4% | -101% | -46.8% | -31.2% | — | 18 |
| ACRS | $615M | — | — | 78.6× | -58.2% | 73.3% | -830% | -63.0% | -63.0% | — | 20 |
| ZVRA | $610M | 7.6× | — | 5.7× | 351% | — | 78.2% | 53.8% | 38.4% | — | 27 |
| MYGN | $607M | — | — | 0.7× | -1.6% | 69.9% | -44.4% | -99.4% | -75.0% | — | 23 |
| IRWD | $578M | 23.3× | 3.6× | 1.9× | -15.7% | — | 8.1% | -9.2% | -9.2% | -2.2× | 36 |
| TROX | $575M | — | 72.6× | 0.2× | -5.7% | 9.3% | -16.2% | -33.1% | -10.2% | — | 37 |
| PBYI | $539M | 17.1× | 14.7× | 2.4× | -0.9% | 74.5% | 13.6% | 23.9% | 17.7% | 0.4× | 31 |
| AMRN | $509M | — | — | 2.4× | -6.5% | 56.6% | -18.2% | -8.4% | -8.4% | — | 9 |
Peers = companies sharing WLKP's sector (Industrial Organic Chemicals) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
| Date | Insider | What it was | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-08-12 | Friel Lisa A. Director | Grant | 5,044 | $0.00 | — |
| 2026-08-12 | Finley G Stephen Director | Grant | 5,044 | $0.00 | — |
| 2026-08-12 | Woelfel Randy Director | Grant | 5,044 | $0.00 | — |
| 2026-08-06 | 3 co-filers Group filing | Option exercise | 5,005 | — | — |
| 2026-08-06 | 2 co-filers Group filing | Option exercise | 5,005 | — | — |
| 2026-08-06 | 3 co-filers Group filing | Option exercise | 5,005 | — | — |
| 2026-08-06 | 2 co-filers Group filing | Option exercise | 5,005 | $0.00 | — |
| 2026-08-06 | 3 co-filers Group filing | Other | 2,502 | $21.35 | $53k |
| 2026-08-06 | 3 co-filers Group filing | Other | 5,005 | $21.35 | $107k |
| 2026-08-06 | 3 co-filers Group filing | Option exercise | 5,005 | $0.00 | — |
| 2026-08-06 | 3 co-filers Group filing | Option exercise | 5,005 | $0.00 | — |
Every row is classified by what it MEANT, not by its SEC code. A code is not a meaning: code P (“purchase”) also covers dividend reinvestment and employee stock purchase plans, and code S (“sale”) also covers 10b5-1 plan sales scheduled months earlier and option exercises sold the same day.
Across 30 days of all filings, $5.08bn of insider selling contained $3.50bn of plan sales and $0.46bn of exercise-and-sell. Only 29% was discretionary. Reading an unclassified feed badly overstates how much insiders decided.
Buys and sales are counted separately and never netted. They are different decisions by different people; a company where one officer bought while another sold is not “neutral”.
The holding line carries each insider's last reported position forward, so it shows the total held rather than a sawtooth of whoever traded that day. It covers only insiders who filed in the window.
“Filed late” counts calendar days past the two-business-day deadline with five days' grace, so a Thursday or Friday trade crossing a weekend is never flagged. It describes the company's filing discipline, not the trade.
Insider activity is descriptive. Nothing here is investment advice.
EOD close · as of 2026-10-30
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
ROIC is not available for this period, so the share of ROE attributable to leverage cannot be separated out.
What the company owes vs. what it holds
This shows debt/cash structure and net leverage. The year-by-year maturity schedule is on the Debt & Leverage tab.
Latest year: profit growth vs revenue growth
Profit and sales moved in opposite directions this year.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 70.7 | 65.2 | 60.8 | 63.6 | 76.3 | 67.5 | 63.1 | 70.2 |
| Gross Profit | 29.3 | 34.8 | 39.2 | 36.4 | 23.7 | 32.5 | 36.9 | 29.8 |
| SG&A | 2.1 | 2.7 | 2.7 | 2.6 | 1.9 | 2.5 | 2.5 | 2.4 |
| Operating Income | 27.2 | 32.1 | 36.5 | 33.8 | 21.8 | 30.0 | 34.4 | 27.4 |
| Income Tax | 0.0 | 0.1 | 0.1 | 0.0 | 0.1 | 0.1 | 0.1 | 0.0 |
| Net Income | 3.8 | 5.6 | 6.8 | 6.8 | 4.0 | 4.6 | 5.5 | 4.2 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on WLKP: price, valuation and headline fundamentals from SEC filings. The four questions at the top of the page are where the judgements live.
Cost of capital cannot be computed, so the spread is unknown.
| Fiscal year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY2016 | 39.7% | 37.1% | 4.1% |
| FY2017 | 34.4% | 31.9% | 4.1% |
| FY2018 | 29.3% | 27.2% | 3.8% |
| FY2019 | 34.8% | 32.1% | 5.6% |
| FY2020 | 39.2% | 36.5% | 6.8% |
| FY2021 | 36.4% | 33.8% | 6.8% |
| FY2022 | 23.7% | 21.8% | 4.0% |
| FY2023 | 32.5% | 30.0% | 4.6% |
| FY2024 | 36.9% | 34.4% | 5.5% |
| FY2025 | 29.8% | 27.4% | 4.2% |
No material counter-signal in the checked set: ROIC vs WACC spread, 5-year spread history, gross margin trend, operating margin trend, net margin against 3 years ago, revenue growth, ROIC ex-goodwill gap.
Missing from our data, so excluded from this answer: wacc.
Converts 5.79x of reported profit into free cash flow over 5 years, with accruals negative.
Capex has been below depreciation for 7 consecutive years (0.53x on average over the last 5). Spending less than the asset base is consuming flatters free cash flow now and defers the cost — though depreciation also covers amortisation of acquired intangibles, which capex is not meant to replace.
Missing from our data, so excluded from this answer: share_based_compensation.
No debt, so there is no leverage path to distress.
Balance sheet at 2025-12-31. Undrawn revolving credit is not shown: the tag is collected but not yet mapped through to the API.
No material counter-signal in the checked set: net debt / EBITDA, interest coverage, stressed coverage, maturity schedule vs cash and one year of FCF, liquidity ratios.
At $21.26, free cash flow must compound -30.34%/yr for 10 years. It has done -11.05%/yr over 6 years.
| Fiscal year | FCF growth | Price requires |
|---|---|---|
| FY2020 | −17.4% | −30.3% |
| FY2021 | −2.7% | −30.3% |
| FY2022 | 25.2% | −30.3% |
| FY2023 | −1.1% | −30.3% |
| FY2024 | 7.6% | −30.3% |
| FY2025 | −53.8% | −30.3% |
The implied rate has been matched or beaten in 5 of the last 6 years.
| Step | Amount | Running total |
|---|---|---|
| Net income | $49M | $49M |
| Share-based comp | not reported | not reported |
| Other non-cash & working capital | $232M | $280M |
| Operating cash flow | $280M | $280M |
| Capex | −$79M | $202M |
| Free cash flow | $202M | $202M |
| Fiscal year | Revenue growth | Receivables growth | Gap |
|---|---|---|---|
| FY2020 | -11.5% | 11.3% | 22.7 points |
| FY2021 | 25.7% | -47.2% | -72.8 points |
| FY2022 | 31.1% | 243.9% | 212.7 points |
| FY2023 | -25.3% | not reported | not reported |
| FY2024 | -4.6% | not reported | not reported |
| FY2025 | 2.7% | not reported | not reported |
| Fiscal year | DSO | DIO | DPO | Cash conversion cycle |
|---|---|---|---|---|
| FY2019 | 3.3 days | 1.3 days | 3.1 days | 1.4 days |
| FY2020 | 4.2 days | 2.2 days | 8.2 days | -1.8 days |
| FY2021 | 1.8 days | 4.2 days | 16.6 days | -10.6 days |
| FY2022 | 4.6 days | 1.4 days | 4.6 days | 1.4 days |
| FY2023 | not reported | 2 days | not reported | not reported |
| FY2024 | not reported | 2.1 days | not reported | not reported |
| FY2025 | not reported | 1.2 days | not reported | not reported |
| Fiscal year | Accruals / assets |
|---|---|
| FY2019 | -28.0 percent |
| FY2020 | -22.6 percent |
| FY2021 | -22.0 percent |
| FY2022 | -29.1 percent |
| FY2023 | -30.2 percent |
| FY2024 | -32.8 percent |
| FY2025 | -18.4 percent |
Below the line, the asset base is being consumed faster than it is replaced.
Below the line for 7 consecutive years to the latest.
Depreciation here includes amortisation of acquired intangibles — goodwill written down over time, customer lists, acquired technology. Capex does not replace those and is not meant to, so an acquisitive or asset-light company sits below 1.0 permanently and correctly. The signal is cleanest for capital-intensive businesses, where the two measure the same physical base. For that reason this informs the earnings-quality verdict but never caps it.